<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923583</url>
  </required_header>
  <id_info>
    <org_study_id>MOM-M834-001</org_study_id>
    <nct_id>NCT02923583</nct_id>
  </id_info>
  <brief_title>Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of M834 (Abatacept Biosimilar Candidate), US-Sourced Orencia®, and European Union (EU)-Sourced Orencia® in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Momenta Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is assess the pharmacokinetics and safety of M834 and Orencia ®&#xD;
      following administration of a single-dose in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 21, 2017</completion_date>
  <primary_completion_date type="Actual">July 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Pre-dose; and post dose through day 85.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration (AUC) versus time curve from zero to last quantifiable concentration [AUC(0-last)]</measure>
    <time_frame>Pre-dose; and post dose through day 85.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in serum from time zero extrapolated to infinity [AUC(0-inf)]</measure>
    <time_frame>Pre-dose; and post dose through day 85.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of anti-drug antibodies (ADAs)</measure>
    <time_frame>Pre-dose; and post dose through day 85.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count and percentages of adverse events by treatment group.</measure>
    <time_frame>Time of dosing up-to Day 85 post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>M834</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M834 (abatacept biosimilar candidate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Orencia®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US-sourced Orencia® (abatacept)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Orencia®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-sourced Orencia® (abatacept)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M834</intervention_name>
    <arm_group_label>M834</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US-Sourced Orencia®</intervention_name>
    <arm_group_label>US Orencia®</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU-Sourced Orencia®</intervention_name>
    <arm_group_label>EU Orencia®</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females 18 to 55 years of age, inclusive (of any ethnic origin).&#xD;
&#xD;
          2. Healthy as determined by medical history, physical examination, vital signs, and 12&#xD;
             lead electrocardiography (ECG) at screening.&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 32 kg/m2.&#xD;
&#xD;
          4. Body weight between 50.0 and 100.0 kg, inclusive.&#xD;
&#xD;
          5. Has smoked no more than 10 cigarettes, 3 cigars, or 3 pipes/day for at least 1 month&#xD;
             prior to screening and is willing to comply with smoking restrictions during&#xD;
             confinement at the study center.&#xD;
&#xD;
          6. Willing and able to comply with the requirements of the study.&#xD;
&#xD;
          7. Willing and able to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History and/or current presence of clinically significant angioedema, clinically&#xD;
             significant hypersensitivity, or severe allergic reactions (either spontaneous or&#xD;
             following drug administration), also including known or suspected clinically relevant&#xD;
             drug hypersensitivity to any components of the study drugs or comparable drugs, or&#xD;
             latex.&#xD;
&#xD;
          2. History of invasive systemic fungal infections (e.g., histoplasmosis,&#xD;
             coccidioidomycosis) or other severe opportunistic infections; subjects with&#xD;
             well-controlled or mild recurrent or chronic local fungal infections (e.g., tinea&#xD;
             versicolor, onychomycosis, athlete's foot) may be included at the discretion of the&#xD;
             Investigator.&#xD;
&#xD;
          3. A serious infection (associated with hospitalization and/or required intravenous&#xD;
             anti-infectives) within 6 months of study drug administration or a significant&#xD;
             infection requiring oral or topical anti-infectives within 4 weeks of study drug&#xD;
             administration.&#xD;
&#xD;
          4. Any minor infection within 2 weeks of admission to the clinical unit on Day -1 that,&#xD;
             in the opinion of the Investigator, may require systemic therapy or otherwise impact&#xD;
             safety or participation in the study.&#xD;
&#xD;
          5. Herpes zoster infection in the last year or more than 1 herpes zoster infections in&#xD;
             his/her lifetime.&#xD;
&#xD;
          6. Frequent chronic or recurrent infections (defined as &gt;3 a year requiring prescribed&#xD;
             antibiotic treatment; subjects with &gt;3 viral upper respiratory infections may be&#xD;
             considered based on Investigator discretion).&#xD;
&#xD;
          7. Previous administration of abatacept, belatacept, or biosimilar candidates referencing&#xD;
             abatacept or belatacept.&#xD;
&#xD;
          8. Receipt of another recombinant human monoclonal antibody within 6 months prior to&#xD;
             dosing in this trial, or within 5 half-lives, or within the expected period of&#xD;
             pharmacodynamic effect; whichever is longest.&#xD;
&#xD;
          9. Intake of any study drug in another trial within 3 months prior to dosing in this&#xD;
             trial or have received the last dose of an investigational drug &gt;3 months ago but who&#xD;
             are on extended follow-up, or planned dosing of an investigational drug (other than&#xD;
             for this study) during the course of this trial.&#xD;
&#xD;
         10. History of alcohol abuse in the past year, or history of regular consumption of&#xD;
             alcohol, or unwillingness to comply with the alcohol restrictions outlined.&#xD;
&#xD;
         11. History of drug abuse.&#xD;
&#xD;
         12. Donation of blood within 3 months or blood products (e.g., platelets within 6 weeks,&#xD;
             plasma within 7 days) prior to dosing.&#xD;
&#xD;
         13. Use of any prescribed or non-prescribed medication, dietary supplements or herbal&#xD;
             medication during the 2 weeks prior to dosing.&#xD;
&#xD;
         14. History of or current congestive heart failure.&#xD;
&#xD;
         15. History of or current signs or symptoms of demyelinating disease including optic&#xD;
             neuritis and/or multiple sclerosis.&#xD;
&#xD;
         16. History of any cancer including lymphoma, leukemia, skin cancer and cervical carcinoma&#xD;
             in situ.&#xD;
&#xD;
         17. History of immunodeficiency (including those subjects with a positive test for human&#xD;
             immunodeficiency virus [HIV] I and II at screening) or other clinically significant&#xD;
             immunological disorders, or auto-immune disorders. Clinically relevant history or&#xD;
             presence of respiratory, gastrointestinal, renal, hepatic, hematological, metabolic,&#xD;
             lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary,&#xD;
             immunological, dermatological, connective tissue diseases or disorders as judged by&#xD;
             the investigator.&#xD;
&#xD;
         18. Received a live vaccine within 12 weeks prior to clinic admission (Day -1) or plan to&#xD;
             receive a live vaccine during the study (up to and including Day 71).&#xD;
&#xD;
         19. Pregnant or breast-feeding women.&#xD;
&#xD;
         20. Men or women of childbearing potential who are unwilling to practice adequate&#xD;
             contraception during the study (adequate contraceptive measures include use of a&#xD;
             condom with spermicide and one of the following highly effective methods: stable use&#xD;
             of oral contraceptives or other prescription pharmaceutical contraceptive,&#xD;
             intrauterine device (IUD); bilateral tubal ligation, vasectomy, additional barrier&#xD;
             method [e.g., diaphragm, cap, sponge]).&#xD;
&#xD;
               -  Contraception is not required for subjects who are abstinent (abstinence should&#xD;
                  be their preferred and usual lifestyle; contraception should be used as described&#xD;
                  if subjects stop being abstinent), subjects in exclusive same-sex relationships,&#xD;
                  and post-menopausal females.&#xD;
&#xD;
                    -  Postmenopausal women must be amenorrheic for at least 12 months, confirmed&#xD;
                       by follicle-stimulating hormone (FSH) level &gt;40 IU/L at screening in order&#xD;
                       not to be considered of childbearing potential. Pregnancy testing and&#xD;
                       contraception are not required for women with documented hysterectomy,&#xD;
                       bilateral salpingectomy, or bilateral oophorectomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candida Fratazzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Momenta Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Bush, MBChB, PhD, MRCS(Ed), MFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clincal Research Unit Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

